Abstract
Adoptive cell treatment utilising chimeric antigen receptor (CAR) immunotherapy is gaining remarkable breakthroughs. In solid tumours, CAR immunotherapy lags far behind. CAR T cell production, does not have tumor-specific antigens, and is not effective in CAR T cell infiltration and trafficking into tumour sites, therapy-associated toxicity, immunosuppressive TME, and antigen escape are among the primary obstacles for CAR immunotherapy in solid tumours. Compared to CAR T cells, CAR NK cells have a number of benefits, including the ability to be processed from preexisting cell lines with mismatched MHC, the ability to kill bad cells via CAR-independent and CAR-dependent pathway with less toxicity. One clinical study demonstrated the effectiveness and safety of CAR NK cell treatment. However, CAR NK cell therapy also has its drawbacks, including, low persistence, lack of transporting pathway, immunosuppressive tumour microenvironment, and low lentivirus transduction efficiency. Solving these issues are significantly important for this technology to be accepted in future use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
